Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Recruiting × Fruquintinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 256 Carcinoma, Non-Small-Cell Lung 244 Prostatic Neoplasms 140 Colorectal Neoplasms 124 Carcinoma, Hepatocellular 123 Neoplasms 113 Leukemia, Myeloid, Acute 106 Lung Neoplasms 96 Squamous Cell Carcinoma of Head and Neck 89 Multiple Myeloma 85 Pancreatic Neoplasms 84 Triple Negative Breast Neoplasms 83 Ovarian Neoplasms 79 Recurrence 78 Stomach Neoplasms 77 Neoplasm Metastasis 70 Melanoma 63 Lymphoma, Large B-Cell, Diffuse 62 Sarcoma 58 Esophageal Neoplasms 58 Rectal Neoplasms 55 Uterine Cervical Neoplasms 54 Precursor Cell Lymphoblastic Leukemia-Lymphoma 53 Head and Neck Neoplasms 53 Glioblastoma 51 Brain Neoplasms 50 Carcinoma, Renal Cell 48 Cholangiocarcinoma 46 Endometrial Neoplasms 45 Lymphoma 43

Interventions

raltitrexed 1 potassium oxonate 1 gimeracil 1 Tegafur 1 S 1 (combination) 1 HMPL-013 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06427005 2025-01-22

Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC

West China Hospital

Phase 2 Recruiting

Fruquintinib

Data powered by HemOnc (CC BY 4.0) Colophon ⚡